Blow for Spectranetics as leg artery treatment refused
This article was originally published in Clinica
Spectranetics received a blow yesterday when a US FDA advisory panel recommended against approving its laser angioplasty treatment for critical limb ischaemia.
You may also be interested in...
The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.